UB Paderborn / Katalog / Suche / in CDI

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

1 – 25 von 1.127

Sortiert nach

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders

Journal of cancer research and clinical oncology, 2023-12, Vol.149 (18), p.16355-16363

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Link zum Volltext

Verfügbarkeit prüfen

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii147

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Annals of oncology, 2018-10, Vol.29, p.viii344-viii344

2018

Link zum Volltext

Verfügbarkeit prüfen

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

British journal of cancer, 2010-11, Vol.103 (10), p.1588-1596

2010

Link zum Volltext

Verfügbarkeit prüfen

2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

European journal of cancer (1990), 2015-09, Vol.51, p.S545-S545

2015

Link zum Volltext

Verfügbarkeit prüfen

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-10, Vol.390 (10106), p.1949-1961

2017

Link zum Volltext

Verfügbarkeit prüfen

Academic Opportunities within Clinical Oncology Training

Clinical oncology (Royal College of Radiologists (Great Britain)), 2013-07, Vol.25 (7), p.446-446

2013

Link zum Volltext

Verfügbarkeit prüfen

47P Prevalence of mutations in common tumour types in Northern England and utility of Experimental Cancer Medicine Centre (ECMC) CRUK Trial Finder

Annals of oncology, 2022-03, Vol.33, p.S21

2022

Link zum Volltext

Verfügbarkeit prüfen

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2020-09, Vol.31, p.S615-S616

2020

Link zum Volltext

Verfügbarkeit prüfen

Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623)

Gynecologic oncology, 2019-06, Vol.154, p.11-12

2019

Link zum Volltext

Verfügbarkeit prüfen

991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study

Annals of oncology, 2021-09, Vol.32, p.S845-S846

2021

Link zum Volltext

Verfügbarkeit prüfen

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Link zum Volltext

Verfügbarkeit prüfen

EP295 Investigating the effect of hypercapnia, hypoxia and pH on cellular proliferation in cervical cancer

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A215-A215

2019

Link zum Volltext

Verfügbarkeit prüfen

Emerging treatment options for ovarian cancer: focus on rucaparib

International journal of women's health, 2017-01, Vol.9, p.913-924

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours

Annals of oncology, 2017-09, Vol.28, p.v128-v128

2017

Link zum Volltext

Verfügbarkeit prüfen

OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S209-S209

2019

Link zum Volltext

Verfügbarkeit prüfen

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Gynecologic oncology, 2018-06, Vol.149, p.246-247

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Annals of oncology, 2017-09, Vol.28, p.v330-v331

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Study of the Parp Inhibitor E7449 As a Single Agent in Patients with Advanced Solid Tumors or B-Cell Lymphoma

Annals of oncology, 2014-09, Vol.25, p.iv151

2014

Link zum Volltext

Verfügbarkeit prüfen

A biomarker-guided first-in-human trial of subcutaneous ALM201 in patients with solid tumours

Annals of oncology, 2016-10, Vol.27, p.vi42-vi42

2016

Link zum Volltext

Verfügbarkeit prüfen

The role of PARP in DNA repair and its therapeutic exploitation

DNA Repair in Cancer Therapy, 2016, p.115-134

Second Edition, 2016

Link zum Volltext

Verfügbarkeit prüfen

Affective variables, learning approaches and academic achievement: a causal modelling investigation with Hong Kong tertiary students

British journal of educational psychology, 1998-06, Vol.68 (2), p.173-188

1998

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2–mutated, advanced ovarian and/or locally advanced or metastatic breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3104-3104

2011

Link zum Volltext

Verfügbarkeit prüfen

INVESTIGATING THE EFFECT OF HYPERCAPNIA, HYPOXIA AND PH ON CELLULAR PROLIFERATION IN CERVICAL CANCER: EP295

International journal of gynecological cancer, 2019-11, Vol.29 ESGO Annual Meeting Abstracts, p.A215-A215

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.127

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(960)
Mit Volltextzugriff
(994)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

n.n

Thema

Science & Technology
(679)
Life Sciences & Biomedicine
(421)
Humans
(285)
Physical Sciences
(191)
Animals
(172)
Female
(152)
Male
(151)
Technology
(121)
Biological And Medical Sciences
(115)
Mice
(97)
Medical Sciences
(83)
Chemistry
(77)
Physics
(77)
Exact Sciences And Technology
(76)
Middle Aged
(61)
Engineering
(60)
Science & Technology - Other Topics
(60)
Adult
(55)
Aged
(55)
Oncology
(55)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(517)
MEDLINE
(425)
Ingenta.com
(403)
Journals@Ovid Full Text
(292)
NUS Single-Journal Subscriptions
(284)
ScienceDirect
(175)
IngentaConnect Journals
(149)
Wiley Online Library
(141)
EZB-NALI5-00465 Elsevier Archive NL
(117)
JSTOR
(83)
Wiley Online Library
(80)
Nature Journals Online
(65)
Oxford Journals
(64)
SpringerLink (Online service)
(62)
IEEE Xplore
(55)
American Physical Society Journals
(32)
Nexis
(32)
EZB-NALI2-00462 Springer Archive NL
(30)
Oxford Journals 2020 Medicine
(26)
PROLA
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt